INTRODUCTION {#s1}
============

Coronary heart disease (CHD) is one of the leading causes of mortality and morbidity worldwide \[[@R1], [@R2]\]. Besides environmental risk factors (e.g. smoking, drinking, and sedentary lifestyle *et al*.), genetic factors, such as single-nucleotide polymorphisms (SNPs), may play prominent roles in the development of CHD \[[@R3]\].

Vascular endothelial growth factor (VEGFA) is a glycoprotein molecule generated by the vascular endothelium, retinal pigment epithelium, pericytes, T cells and macrophages *et al* \[[@R4]\]. VEGFA, one of the most potent mitogens, acts as an important promoter of angiogenesis in both lymphogenesis and angiogenesis \[[@R5], [@R6]\]. It was reported that inflammation and neovascularization in atheromatous plaques might be mediated by VEGFA \[[@R7]\]. Previous study also found that increased plasma VEGFA levels in CHD patients may indicate the severity of coronary lesion, and it may be adopted as an indicator of the need for revascularization \[[@R8], [@R9]\]. These results suggested that VEGFA might be involved in the development of CHD.

The *VEGF* gene, also named as vascular permeability factor, is located on chromosome 6p21.3 and contains eight exons \[[@R10]\]. VEGF family consists of VEGFA, VEGFB, VEGFC, VEGFD, VEGFE, VEGFF and placental growth factor. The human *VEGFA* gene is very polymorphic (<http://www.ncbi.nlm.nih.gov/SNP>). And the variants of *VEGFA* gene may influence the expression between individuals \[[@R11]\]. Functional studies indicated that a number of variants in *VEGFA* gene were correlated with the level of mRNA and protein expression \[[@R12], [@R13]\]. Three single nucleotide polymorphisms (SNPs), *VEGFA* rs699947 (−2578C \> A), rs3025039 (+936C \> T) and rs2010963 G \> C were extensively studied their associations with CHD; however, the results remained inconsistent. Recently, a systematic review and meta-analysis showed that *VEGFA* rs699947 polymorphism was not associated with CHD \[[@R14]\]. However, in this pooled analysis \[[@R14]\], only three case-control studies focusing on Caucasians were included, the power of this pooled-analyses might be insufficient. Of late, more epidemiologic studies with relatively large sample size focusing on the potential association of *VEGFA* rs699947 C \> A,rs3025039 C \> T and rs2010963 G \> C polymorphisms with CHD risk were carried out. Considering the potential role of *VEGFA* rs699947 C \> A, rs3025039 C \> T and rs2010963 G \> C polymorphism for CHD susceptibility, this coverage might increase the statistical power to assess the association of *VEGFA* rs699947 C \> A, rs3025039 C \> T and rs2010963 G \> C polymorphisms with CHD risk.

RESULTS {#s2}
=======

Characteristics {#s2_1}
---------------

There were two independent groups in a paper conducted by Kangas-Kontio *et al*., we treated them separately \[[@R19]\]. According to the major inclusion and exclusion criteria, ten eligible publications with 22 independent case-control studies \[[@R19]--[@R28]\] were included to extract the data. The flow chart of the detailed publication selection is summarized in Figure [1](#F1){ref-type="fig"}. For *VEGFA* rs699947 C \> A polymorphism, a total of 1,290 CHD cases and 1,456 non-CHD controls from seven independent case-control studies \[[@R19]--[@R24]\] were included in this meta-analysis. The year of publication ranged from 2008 to 2013. Two of these studies were conducted in Asians \[[@R20], [@R21]\] and five studies in Caucasians \[[@R19], [@R22]--[@R24]\]. Using a Goodness-of-fit chi-square calculator, the HWE test was performed; the genotype distributions of controls were all in HWE (*P* \> 0.05). In total, for *VEGFA* rs3025039 C \> T polymorphism, 1,344 CHD cases and 1,563 non-CHD controls from seven independent case-control studies were included \[[@R19]--[@R21], [@R24]--[@R26]\]. The year of publication ranged from 2008 to 2015. Three of these studies were conducted in Asians \[[@R20], [@R21], [@R26]\] and four studies in Caucasians \[[@R19], [@R24], [@R25]\]. The HWE test was conducted; the genotype distributions of controls were all in HWE (*P* \> 0.05). And for *VEGFA* rs2010963 G \> C polymorphism, 1,344 CHD cases and 2610 non-CHD controls from eight independent case-control studies were included \[[@R19]--[@R21], [@R25]--[@R28]\]. The year of publication ranged from 2006 to 2015. Three of these studies were conducted in Asians \[[@R20], [@R21], [@R26]\] and five studies in Caucasians \[[@R19], [@R25], [@R27], [@R28]\]. The HWE test was conducted; the genotype distributions of controls were all in HWE (*P* \> 0.05). The characteristics of the included studies are shown in Table [1](#T1){ref-type="table"}. The genotype distributions of the *VEGFA* rs699947 C \> A, rs3025039 C \> T and rs2010963 polymorphisms in CHD cases and controls are presented in Table [2](#T2){ref-type="table"}, Table [3](#T3){ref-type="table"} and Table [4](#T4){ref-type="table"}, respectively.

![Flow diagram of studies selection](oncotarget-08-30539-g001){#F1}

###### Characteristics of the eligible studies in the meta-analysis

  study                    year   country    ethnicity    CHD type                 No. of cases/controls   Genotype Method   polymorphisms
  ------------------------ ------ ---------- ------------ ------------------------ ----------------------- ----------------- --------------------------------------------------
  Han *et al*.             2015   China      Asians       coronary heart disease   144/150                 MALDI-TOF MS      rs3025039 C\>T and rs2010963 G\>C
  Moradzadegan et al.      2015   Iran       Caucasians   coronary heart disease   141/369                 PCR-RFLP          rs2010963 G\>C
  Gu *et al*.              2013   China      Asians       coronary heart disease   435/480                 MALDI-TOF MS      rs699947 C\>A, rs3025039 C\>T and rs2010963 G\>C
  Cui *et al*.             2013   China      Asians       coronary heart disease   242/253                 MALDI-TOF MS      rs699947 C\>A, rs3025039 C\>T and rs2010963 G\>C
  Amoli *et al*.           2012   Iran       Caucasians   coronary heart disease   50/50                   ARMS--PCR         rs699947 C\>A
  Guerzoni *et al*.        2009   Brazil     Caucasians   coronary heart disease   145/99                  PCR-SSCP          rs699947 C\>A
  Douvaras *et al*.        2009   Greece     Caucasians   myocardial infarction    102/98                  PCR-RFLP          rs3025039 C\>T and rs2010963 G\>C
  Kangas-Kontio *et al*.   2009   Finland    Caucasians   myocardial infarction    215/218                 TaqMan            rs699947 C\>A, rs3025039 C\>T and rs2010963 G\>C
  Kangas-Kontio *et al*.   2009   Finland    Caucasians   myocardial infarction    36/263                  TaqMan            rs699947 C\>A, rs3025039 C\>T and rs2010963 G\>C
  Biselli *et al*.         2008   Brazil     Caucasians   coronary heart disease   175/108                 PCR-SSCP          rs699947 C\>A and rs3025039 C\>T
  Petrovic et al.          2006   Slovenia   Caucasians   myocardial infarction    143/228                 PCR-RFLP          rs2010963 G\>C

Abbreviations: MALDI-TOF MS, Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry; ARMS-PCR, Amplification Refractory Mutation System-Polymerase Chain Reaction; PCR-SSCP, Polymerase Chain Reaction-Single-Strand Conformational Polymorphism; PCR-RFLP, Polymerase Chain Reaction -Restriction Fragment Length Polymorphism.

###### Distribution of *VEGFA* rs699947 C\>A polymorphism genotypes and alleles

  study                  year   Case genotype   Control genotype   Case allele   Control allele   HWE                                
  ---------------------- ------ --------------- ------------------ ------------- ---------------- ----- ---- ----- ----- ----- ----- -----
  Gu et al.              2013   219             178                30            267              174   31   616   238   708   236   YES
  Cui et al.             2013   137             78                 27            172              69    12   352   132   413   93    YES
  Amoli et al.           2012   9               27                 14            15               26    9    45    55    56    44    YES
  Guerzoni et al.        2009   34              83                 28            29               46    24   151   139   104   94    YES
  Kangas-Kontio et al.   2009   36              104                75            40               101   70   176   254   181   241   YES
  Kangas-Kontio et al.   2009   4               18                 14            53               129   81   26    46    235   291   YES
  Biselli et al.         2008   47              96                 32            30               51    27   190   160   111   105   YES

Abbreviation: HWE, Hardy--Weinberg equilibrium

###### Distribution of *VEGFA* rs3025039 C\>T polymorphism genotypes and alleles

  study                  year   Case genotype   Control genotype   Case allele   Control allele   HWE                                
  ---------------------- ------ --------------- ------------------ ------------- ---------------- ----- ---- ----- ----- ----- ----- -----
  Han et al.             2015   84              55                 5             115              31    4    223   65    261   39    YES
  Gu et al.              2013   272             142                16            300              159   14   686   174   759   187   YES
  Cui et al.             2013   133             95                 14            159              86    8    361   123   404   102   YES
  Douvaras et al.        2009   68              30                 4             69               27    2    166   38    165   31    YES
  Kangas-Kontio et al.   2009   160             50                 5             155              56    7    370   60    366   70    YES
  Kangas-Kontio et al.   2009   23              13                 0             184              72    7    59    13    440   86    YES
  Biselli et al.         2008   133             36                 6             83               23    2    302   48    189   27    YES

Abbreviation: HWE, Hardy--Weinberg equilibrium

###### Distribution of *VEGFA* rs2010963 G\>C polymorphism genotypes and allelles

                         year   Case genotype   Control genotype   Case allele   Control allele   HWE                                
  ---------------------- ------ --------------- ------------------ ------------- ---------------- ----- ---- ----- ----- ----- ----- -----
  Han et al.             2015   69              49                 26            86               54    10   187   101   226   74    YES
  Moradzadegan et al.    2015   43              65                 33            85               197   87   151   131   367   371   YES
  Gu et al.              2013   144             215                60            154              225   89   503   335   533   403   YES
  Cui et al.             2013   75              102                65            104              114   35   252   232   322   184   YES
  Douvaras et al.        2009   37              49                 16            29               55    14   123   81    113   83    YES
  Kangas-Kontio et al.   2009   132             72                 10            143              67    8    336   92    353   83    YES
  Kangas-Kontio et al.   2009   22              10                 3             154              90    19   54    16    398   128   YES
  Petrovic et al.        2006   42              76                 25            103              104   21   160   126   310   146   YES

Abbreviation: HWE, Hardy--Weinberg equilibrium

Quantitative synthesis {#s2_2}
----------------------

Overall, *VEGFA* rs699947 C \> A polymorphism was a risk factor for CHD (A *vs*. C: OR = 1.19; 95% CI, 1.05 - 1.34; *P* = 0.005; AA *vs*. CC: OR = 1.33; 95% CI, 1.03-1.73; *P* = 0.032 and AA+CA *vs*. CC: OR = 1.33; 95% CI, 1.12-1.58; *P* = 0.001; Table [5](#T5){ref-type="table"} and Figure [2](#F2){ref-type="fig"}). In subgroup analyses by ethnicity, the similar association was found among Asians (AA+CA *vs*. CC: OR = 1.36; 95% CI, 1.10-1.68; *P* = 0.005; Table [5](#T5){ref-type="table"}). In subgroup analyses by the type of CHD, *VEGFA* rs699947 C \> A polymorphism was also associated with risk of non-MI (AA+CA *vs*. CC: OR = 1.34; 95% CI, 1.11-1.60; *P* = 0.002; Table [5](#T5){ref-type="table"}).

###### Meta-analysis of the *VEGFA* rs699947 C\>A polymorphism and CHD

                No. of study   Allelic comparison    Homozygote comparison   Dominant comparison   Recessive comparison                                                                                           
  ------------- -------------- --------------------- ----------------------- --------------------- ---------------------- ----------- ------- --------------------- ----------- ------- ----------------- ------- -------
  Overall       7              **1.19(1.05-1.34)**   **0.005**               0.117                 **1.33(1.03-1.73)**    **0.032**   0.131   **1.33(1.12-1.58)**   **0.001**   0.716   1.14(0.83-1.55)   0.422   0.085
  Ethnicity                                                                                                                                                                                                       
  Asians        2              1.37(0.96-1.95)       0.084                   0.053                 1.76(0.75-4.14)        0.192       0.055   **1.36(1.10-1.68)**   **0.005**   0.233   1.59(0.69-3.66)   0.275   0.056
  Caucasians    5              1.09(0.92-1.28)       0.324                   0.388                 1.17(0.84-1.64)        0.361       0.311   1.28(0.97-1.70)       0.080       0.705   0.99(0.76-1.28)   0.947   0.273
  Type of CHD                                                                                                                                                                                                     
  MI            2              1.15(0.91-1.47)       0.242                   0.349                 1.36(0.83-2.24)        0.220       0.319   1.30(0.83-2.03)       0.245       0.362   1.15(0.81-1.64)   0.432   0.503
  Non-MI        5              1.20(0.96-1.50)       0.108                   0.055                 1.36(0.84-2.21)        0.213       0.065   **1.34(1.11-1.60)**   **0.002**   0.582   1.13(0.71-1.82)   0.604   0.032

Abbreviations: MI: myocardial infarction;

CHD: coronary heart disease

![Meta-analysis for the association between *VEGFA* rs699947 C \> A polymorphism and CHD risk (AA+CA *vs*. CC genetic model, fixed-effects model)](oncotarget-08-30539-g002){#F2}

For *VEGFA* rs3025039 C \> T polymorphism, this SNP was associated with increased risk of overall CHD in one genetic models (T *vs*. C: OR = 1.16; 95% CI, 1.01 - 1.33; *P* = 0.035; Table [6](#T6){ref-type="table"} and Figure [3](#F3){ref-type="fig"}). However, in a subgroup analysis by ethnicity and the type of CHD, the association was not identified (Table [6](#T6){ref-type="table"}).

###### Meta-analysis of the *VEGFA* rs3025039 C\>T polymorphism and CHD

                No. of study   Allelic comparison    Homozygote comparison   Dominant comparison   Recessive comparison                                                                               
  ------------- -------------- --------------------- ----------------------- --------------------- ---------------------- ------- ------- ----------------- ------- ------- ----------------- ------- -------
  Overall       7              **1.16(1.01-1.33)**   0.035                   0.114                 1.40(0.91-2.15)        0.125   0.800   1.21(0.95-1.55)   0.117   0.065   1.33(0.87-2.04)   0.189   0.862
  Ethnicity                                                                                                                                                                                           
  Asians        3              1.34(0.96-1.87)       0.089                   0.031                 1.57(0.93-2.65)        0.089   0.687   1.42(0.91-2.22)   0.119   0.012   1.46(0.87-2.45)   0.149   0.786
  Caucasians    4              1.01(0.80-1.29)       0.906                   0.661                 1.09(0.51-2.33)        0.825   0.626   1.02(0.77-1.33)   0.914   0.686   1.09(0.51-2.31)   0.832   0.635
  Type of CHD                                                                                                                                                                                         
  MI            3              0.99(0.75-1.30)       0.926                   0.490                 0.91(0.38-2.20)        0.835   0.555   1.01(0.74-1.37)   0.974   0.480   0.91(0.38-2.17)   0.823   0.569
  Non-MI        4              1.29(0.98-1.68)       0.065                   0.068                 1.60(0.98-2.63)        0.063   0.852   1.33(0.93-1.90)   0.113   0.027   1.50(0.92-2.45)   0.106   0.904

Abbreviations: MI: myocardial infarction;

CHD: coronary heart disease

![Meta-analysis for the association between VEGFA rs3025039 C \> T polymorphism and CHD risk (T *vs*. C genetic model; fixed-effects model)](oncotarget-08-30539-g003){#F3}

For *VEGFA* rs2010963 G \> C polymorphism, this SNP was not associated with risk of overall CHD (Table [7](#T7){ref-type="table"}). However, in a subgroup analysis by the type of CHD, the polymorphism was associated with MI risk (CC *vs*. GG: OR = 1.62; 95% CI, 1.05 - 2.50; *P* = 0.029; CC *vs*. CG+GG: OR = 1.51; 95% CI, 1.01 - 2.27; *P* = 0.047; Table [7](#T7){ref-type="table"} and Figure [4](#F4){ref-type="fig"}).

###### Meta-analysis of the *VEGFA* 2010963 G\>C polymorphism and CHD

                No. of study   Allelic comparison   Homozygote comparison   Dominant comparison   Recessive comparison                                                                                             
  ------------- -------------- -------------------- ----------------------- --------------------- ---------------------- ----------- --------- ----------------- ------- ------- --------------------- ----------- ---------
  Overall       8              1.17(0.93,1.47)      0.182                   \<0.001               1.43(0.87,2.35)        0.160       \<0.001   1.12(0.87,1.45)   0.379   0.006   1.41(0.93,2.14)       0.102       0.001
  Ethnicity                                                                                                                                                                                                        
  Asians        3              1.31(0.83,2.06)      0.242                   \<0.001               1.76(0.65,4.78)        0.269       \<0.001   1.25(0.88,1.78)   0.210   0.061   1.65(0.64,4.25)       0.297       \<0.001
  Caucasians    5              1.09(0.82,1.43)      0.562                   0.019                 1.25(0.70,2.21)        0.454       0.042     1.02(0.68,1.54)   0.922   0.008   1.25(0.92,1.69)       0.146       0.450
  Type of CHD                                                                                                                                                                                                      
  MI            4              1.17(0.87,1.59)      0.306                   0.062                 **1.62(1.05,2.50)**    **0.029**   0.163     1.15(0.74,1.78)   0.527   0.038   **1.51(1.01,2.27)**   **0.047**   0.604
  Non-MI        4              1.18,0.83,1.67       0.368                   \<0.001               1.41(0.66,3.00)        0.376       \<0.001   1.09(0.77,1.56)   0.625   0.013   1.43(0.74,2.75)       0.287       \<0.001

Abbreviations: MI: myocardial infarction;

CHD: coronary heart disease

![Meta-analysis for the association between VEGFA 2010963 G \> C polymorphism and CHD risk (CC *vs*. GG genetic model; fixed-effects model)](oncotarget-08-30539-g004){#F4}

Tests for publication bias {#s2_3}
--------------------------

The shape of Begg\'s funnel plot test was symmetrical for *VEGFA* rs699947 C \> A, rs3025039 C \> T and rs2010963 G \> C polymorphisms (rs699947 C \> A polymorphism: A *vs*. C: Begg\'s test *P* = 0.764; AA *vs*. CC: Begg\'s test *P* = 0.368; AA+CA *vs*. CC: Begg\'s test *P* = 0.548 and AA *vs*. CC+CA: Begg\'s test *P* = 0.230; rs3025039 C \> T polymorphism: T *vs*. C: Begg\'s test *P* = 0.764; TT *vs*. CC: Begg\'s test *P* = 1.000; TT+CT *vs*. CC: Begg\'s test *P* = 0.548 and TT *vs*. CT+CC: Begg\'s test *P* = 1.000; rs2010963 G \> C polymorphism: C *vs*. G: Begg\'s test *P* = 1.000; CC *vs*. GG: Begg\'s test *P* = 1.000; CC+GC *vs*. GG: Begg\'s test *P* = 1.000 and CC *vs*. GG+GC: Begg\'s test *P* = 0.902; Figure [5](#F5){ref-type="fig"}, Figure [6](#F6){ref-type="fig"} and Figure [7](#F7){ref-type="fig"}). The statistical results of Egger\'s test still demonstrated there were no evidence of bias for these two SNPs (rs699947 C \> A polymorphism: A *vs*. C: Egger\'s test *P* = 0.627; AA *vs*. CC: Egger\'s test *P* = 0.257; AA+CA *vs*. CC: Egger\'s test *P* = 0.394 and AA *vs*. CC+CA: Egger\'s test *P* = 0.356; rs3025039 C \> T polymorphism: T *vs*. C: Egger\'s test *P* = 0.598; TT *vs*. CC: Egger\'s test *P* = 0.783; TT+CT *vs*. CC: Egger\'s test *P* = 0.475 and TT *vs*. CT+CC: Egger\'s test *P* = 0.660; rs2010963 G \> C polymorphism: C *vs*. G: Egger\'s test *P* = 0.608; CC *vs*. GG: Egger\'s test *P* = 0.445; CC+GC *vs*. GG: Egger\'s test *P* = 0.899 and CC *vs*. GC+GG: Egger\'s test *P* = 0.318).

![Begg\'s funnel plot of meta-analysis for the association between VEGFA rs699947 C \> A polymorphism and CHD risk (AA+CA *vs*. CC genetic model)](oncotarget-08-30539-g005){#F5}

![Begg\'s funnel plot of meta-analysis for the association between VEGFA rs3025039 C \> T polymorphism and CHD risk (T *vs*. C genetic model)](oncotarget-08-30539-g006){#F6}

![Begg\'s funnel plot of meta-analysis for the association between *VEGFA* rs2010963 G \> C polymorphism and CHD risk (CC *vs*. GG genetic model)](oncotarget-08-30539-g007){#F7}

Tests for sensitivity analyses {#s2_4}
------------------------------

An independent study involved in the present pooled-analysis was omitted each time to assess the influence of the data-set on the pooled ORs, and the exclusion of anyone did not materially alter the corresponding pooled ORs (Figure [8](#F8){ref-type="fig"}, Figure [9](#F9){ref-type="fig"} and Figure [10](#F10){ref-type="fig"}, data not shown).

![Sensitivity analysis of the overall CHD meta-analysis for *VEGFA* rs699947 C \> A polymorphism](oncotarget-08-30539-g008){#F8}

![Sensitivity analysis of the overall CHD meta-analysis for *VEGFA* rs3025039 C \> T polymorphism](oncotarget-08-30539-g009){#F9}

![Sensitivity analysis of the overall CHD meta-analysis for *VEGFA* rs2010963 G \> C polymorphism](oncotarget-08-30539-g010){#F10}

Tests for heterogeneity {#s2_5}
-----------------------

In some genetic models, we found significant heterogeneity across studies in the present meta-analysis for *VEGFA* rs699947 C \> A, rs3025039 C \> T and rs2010963 G \> C polymorphisms. Type of CHD and ethnicity were defined as characteristics for evaluation of potential heterogeneity. Results of subgroup analyses demonstrated that studies conducted in Asians and non-MI subgroups may contribute to the major source of heterogeneity for *VEGFA* rs699947 C \> A, rs3025039 C \> T and rs2010963 G \> C polymorphisms.

Results of quality assessment {#s2_6}
-----------------------------

We used Newcastle-Ottawa Quality Assessment Scale to assess the quality score of the eligible studies. When scores ≥ 7 stars, the study was considered as high-quality. The results indicated that all included studies were high-quality, suggesting the reliability of our findings (Table [8](#T8){ref-type="table"}).

###### Quality assessment of the included studies

  Study                    Year   Selection   Comparability of the cases and controls   Exposure   Total stars                             
  ------------------------ ------ ----------- ----------------------------------------- ---------- ------------- ------ ------ ----- ----- ---
  Han *et al*.             2015   \*          \*                                        ---        \*            \*\*   \*\*   \*    ---   8
  Moradzadegan *et al*.    2015   \*          \*                                        ---        \*            \*\*   \*     \*    ---   7
  Gu *et al*.              2013   \*          \*                                        ---        \*            \*\*   \*\*   \*    ---   8
  Cui *et al*.             2013   \*          \*                                        ---        \*            \*\*   \*     \*    ---   7
  Amoli *et al*.           2012   \*          \*                                        ---        \*            \*\*   \*\*   \*    ---   8
  Guerzoni *et al*.        2009   \*          \*                                        ---        \*            \*\*   \*\*   \*    ---   8
  Douvaras *et al*.        2009   \*          \*                                        ---        \*            \*\*   \*\*   ---   ---   7
  Kangas-Kontio *et al*.   2009   \*          \*                                        \*         \*            \*\*   \*\*   \*    ---   9
  Kangas-Kontio *et al*.   2009   \*          \*                                        \*         \*            \*\*   \*\*   \*    ---   9
  Biselli *et al*.         2008   \*          ---                                       ---        \*            \*\*   \*\*   \*    ---   7
  Petrovic et al.          2006   \*          \*                                        ---        \*            \*\*   \*\*   \*    ---   8

DISCUSSION {#s3}
==========

Besides environmental risk factors (e.g. smoking, drinking, and sedentary lifestyle *et al*.), multiple evidences support a vital role of genetics in determining susceptibility for CHD. The involvement of *VEGFA* in inflammation and neovascularization may underlie the major mechanism responsible for the association between *VEGFA* genotypes and risk of CHD. Recently, several investigations on the molecular epidemiology considering on the correlation of *VEGFA* polymorphism with CHD risk were performed; however, the findings remained conflicting. With respect to *VEGFA* polymorphisms, a recent systemic review and meta-analysis with small sample sizes on this issue did not suggest any association between *VEGFA* rs699947 C \> A polymorphism and risk of CHD \[[@R14]\]. After that, some case-control studies reported that rs699947 C \> A polymorphism in *VEGFA* gene have been implicated in CHD risk, especially in Asians. Thus, we conducted a meta-analysis involving a total of 2097 CHD cases and 2867 controls subjects from ten publications including 22 trails to assess the potential associations between two commonly functional SNPs (rs699947 C \> A, rs3025039 C \> T and rs2010963 G \> C) in *VEGFA* gene and CHD risk.

For *VEGFA* rs699947 C \> A polymorphism, seven independent studies focusing on the relationship of this SNP with CHD risk were included. A recent case-control study has reported positive signals of *VEGFA* rs699947 C \> A polymorphism with risk of CHD \[[@R21]\]; contrastingly, others showed the variants of *VEGFA* rs699947 C \> A polymorphism did not influence risk of CHD \[[@R19], [@R20], [@R22]--[@R24]\]. As shown in Table [4](#T4){ref-type="table"}, *VEGFA* rs699947 C \> A polymorphism was identified to be associated with the development of CHD. The A allele carriers indicated higher CHD susceptibility in comparison with the C allele carriers. In subgroup analyses by ethnicity, the similar association was found among Asians, but not Caucasians. Our results were consistent with the findings of a previous meta-analysis \[[@R14]\]. A previous study indicated the expression levels of VEGF mRNA in CHD patients carrying the VEGF rs699947 AA genotype were significantly lower than those who carried the VEGF rs699947 AC or CC genotypes \[[@R29]\]. This study also suggested that CHD patients carrying the VEGF rs699947 A allele might have more chances in developing better coronary collaterals \[[@R29]\]. Gokkusu *et al*. reported that VEGF might be a cardio-protective factor \[[@R30]\]. In this study, we found that *VEGFA* rs699947 C \> A polymorphism was correlated with increased risk of CHD, suggesting the presence of the A allele, which was associated with lower expression of VEGF mRNA and activity, might lead to the increased risk of CHD.

Rs3025039 C \> T polymorphism locates on the 3′-UTR region of *VEGFA* gene. Thus, it may regulate post-transcription and then influence gene expression. *VEGFA* rs3025039 C \> T polymorphism was well known to influence the secreted levels of VEGFA protein and has been identified to have overt association in most studies \[[@R31]\]. This SNP exhibited a very strong association with epithelial ovarian cancer status and poorer prognosis \[[@R31]\]. A prior study indicated this 3′-UTR polymorphism was associated with the occurrence and severity of diabetic nephropathy \[[@R32]\]. Recently, several case-control studies focused on the association between *VEGFA* rs3025039 C \> T polymorphism and CHD risk. Han *et al.* reported that *VEGFA* rs3025039 CT genotype and C allele appeared to be a genetic risk factor for CHD \[[@R26]\]. Cui *et al*. also found *VEGFA* rs3025039 C \> T polymorphism conferred a borderline increased risk to CHD \[[@R21]\]. As demonstrated in Table [5](#T5){ref-type="table"}, the combined evidence suggested that *VEGFA* rs3025039 C \> T polymorphism was a risk factor for overall CHD. In a subgroup analysis by ethnicity and the type of CHD, a borderline increased risk to CHD was also found in Asians and non-MI subgroups (*P* = 0.089 and *P* = 0.065, respectively). These findings demonstrated the presence of the T allele may alter mRNA and secreted levels of VEGFA protein and then led to the increased risk of CHD.

Rs2010963 G \> C polymorphism is located in the 5′-untranslated region in *VEGFA* gene. According to previous reports, rs2010963 G \> C polymorphism was a genetic marker of microvascular complications in cases with type 2 diabetes \[[@R33]--[@R35]\]. Compared to those with *VEGFA* GG and GC genotypes, a remarkably higher VEGF serum level was found in healthy individuals with the *VEGFA* rs2010963 CC genotype \[[@R33], [@R36]\]. The CC genotype of the rs2010963 G \> C polymorphism has been demonstrated to be related to heart failure induced by acute myocardial infarction \[[@R25]\]. Several studies have investigated the association between *VEGFA* rs2010963 G \> C polymorphism and CHD risk. After meta-analyses in our study, we concluded that the CC genotype of the polymorphism may increase risk of MI.

Similar to other meta-analyses, some potential limitations of our meta-analysis should be acknowledged. First, although bias tests showed there was no significant publication bias in our meta-analysis and a comprehensive literature search was well designed, it is likely that certain unpublished studies might be overlooked. Second, the association of *VEGFA* rs699947 C \> A, rs3025039 C \> T and rs2010963 G \> C polymorphisms with risk of CHD was assessed based on unadjusted estimates. If the detailed data of individuals were available, a more precise meta-analysis could be carried out. Third, for lack of individual-level data, we did not conduct a further analysis to assess any potential interactions between gene-gene and gene-metabolic traits. Finally, significant heterogeneity between the eligible studies for *VEGFA* rs699947 C \> A, rs3025039 C \> T and rs2010963 G \> C polymorphisms was found. Our results should be interpreted with very cautions.

In conclusion, our findings indicate that *VEGFA* rs699947 C \> A, rs3025039 C \> T and rs2010963 G \> C polymorphisms may be risk factors for the development of CHD. As the participants in some subgroup are currently limited, further well-designed studies with larger sample size to investigate the role of these loci are needed. Moreover, interactions of gene-gene and gene-environment should not be ignored.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

Genetic association publications published before the end of November 15, 2016 on CHD and polymorphisms in *VEGFA* gene were retrieved through a search of PubMed and EMBASE online databases with keywords: (vascular endothelial growth factor-A or VEGFA) and and (polymorphism or variant or SNP) and (coronary artery disease or CAD or coronary heart disease or CHD or myocardial infarction or MI). All bibliographies cited in eligible publications, reviews and meta-analysis were examined to retrieve the potential publications.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

The major criteria of eligible studies were: (a) studies focused on the relationship of *VEGFA* rs699947 C \> A, rs3025039 C \> T and rs2010963 G \> C polymorphisms with CHD risk; (b) sufficient data were presented to determine the odds ratios (ORs) with their 95% confidence intervals (CIs) and *P* value, and (c) the genotyping method, equipment, and protocols used or provided reference were described in publication. Accordingly, publications providing insufficient data, CHD treatment, not case-control design, overlapping data, reviews and meta-analysis were excluded.

Data extraction {#s4_3}
---------------

Two authors (Y. Wang and Q. Huang) reviewed and collected information independently from eligible studies in accordance with the major criteria for inclusion and exclusion mentioned above. The following data: the surname of first author, year of publication, country, ethnicity of the participants, type of CHD \[myocardial infarction (MI) or non-MI\], genotyping method as well as allele and genotype frequencies, were entered into a database. In case of conflicting evaluations, disagreements over study/data inclusion were resolved by a discussion among all reviewers.

Quality assessment {#s4_4}
------------------

The Newcastle-Ottawa Quality Assessment Scale was harnessed to assess the quality score of the eligible studies. And scores ≥ 7 stars were considered as high-quality study \[[@R15]\].

Statistical analysis {#s4_5}
--------------------

A Goodness-of-fit chi-square calculator (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>) was used to examine the deviation from HWE in controls. The strength of correlation between SNPs in *VEGFA* gene and CHD risk was assessed by ORs with the corresponding 95% CIs. Type of CHD (MI or non-MI) and ethnicity were considered as characteristics for evaluation of potential heterogeneity. Ethnicity group was defined as Asians and Caucasians. We used Chi-square based *I*^2^-statistic test and Q statistical test to analyze the potential heterogeneity among the studies. *P* \< 0.10 or *I*^2^ \> 50% indicates high heterogeneity, random-effects model (the DerSimonian and Laird method) was used to calculate the pooled ORs and CIs \[[@R16]\]; otherwise, the fixed-effects model (the Mantel-Haenszel method) was used \[[@R17]\]. Funnel plots and Egger\'s regression test were harnessed to diagnose the potential publication bias \[[@R18]\], and a *P* \< 0.1 was defined as statistical significance. Sensitivity analysis, which assessed the influence of each independent study on the pooled ORs with their corresponding 95% CIs, was also carried out to evaluate the stability of our results. All *P* values were defined as two-sided at the *P* = 0.05 level. All data analysis was performed with Stata 12.0 software for windows (Stata Corporation, College Station, TX).
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